Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Dicerna brings in $29mm through its Series B venture round

Executive Summary

Dicerna Pharmaceuticals Inc. (RNA interference therapeutics) has raised $25mm through its Series B venture round. New backer Domain Associates led (and contributes a board member) and was joined by current shareholders Oxford Bioscience Partners, Skyline Ventures, and Abingworth. Dicerna will use some of the proceeds to develop conjugated drug delivery systems, move its lead cancer program into the clinic, and work on its other preclinical drug candidates.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
      • Site Specific
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
    • Nanotechnology, Chips, etc.
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies